Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5DC4

CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL A

5DC4 の概要
エントリーDOI10.2210/pdb5dc4/pdb
関連するPDBエントリー5DC0 5DC9
分子名称Tyrosine-protein kinase ABL1, AS25 monobody, GLYCEROL, ... (4 entities in total)
機能のキーワードengineered binding protein, antibody mimic, protein-protein complex, sh2 domain, tyrosine-protein kinase, protein binding
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数2
化学式量合計24088.58
構造登録者
Wojcik, J.B.,Koide, A.,Koide, S. (登録日: 2015-08-23, 公開日: 2016-03-02, 最終更新日: 2024-03-06)
主引用文献Wojcik, J.,Lamontanara, A.J.,Grabe, G.,Koide, A.,Akin, L.,Gerig, B.,Hantschel, O.,Koide, S.
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.
J.Biol.Chem., 291:8836-8847, 2016
Cited by
PubMed Abstract: Bcr-Abl is a constitutively active kinase that causes chronic myelogenous leukemia. We have shown that a tandem fusion of two designed binding proteins, termed monobodies, directed to the interaction interface between the Src homology 2 (SH2) and kinase domains and to the phosphotyrosine-binding site of the SH2 domain, respectively, inhibits the Bcr-Abl kinase activity. Because the latter monobody inhibits processive phosphorylation by Bcr-Abl and the SH2-kinase interface is occluded in the active kinase, it remained undetermined whether targeting the SH2-kinase interface alone was sufficient for Bcr-Abl inhibition. To address this question, we generated new, higher affinity monobodies with single nanomolar KD values targeting the kinase-binding surface of SH2. Structural and mutagenesis studies revealed the molecular underpinnings of the monobody-SH2 interactions. Importantly, the new monobodies inhibited Bcr-Abl kinase activity in vitro and in cells, and they potently induced cell death in chronic myelogenous leukemia cell lines. This work provides strong evidence for the SH2-kinase interface as a pharmacologically tractable site for allosteric inhibition of Bcr-Abl.
PubMed: 26912659
DOI: 10.1074/jbc.M115.707901
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.48 Å)
構造検証レポート
Validation report summary of 5dc4
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon